Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Investor Presentation (October 2025)
6 slides from Pyc Therapeutics's investor presentation, Oct 13, 2025
Slide 1: Life-changing science: Investor webinar October 2025
For personal use only Life-changing science Investor webinar October 2025
Slide 2: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business which are outside PYC’s control. Important factors that could cause For personal use only of PYC Therapeutics Limited (ASX:PYC) [‘PYC’]. These slides have been actual results to differ materially from assumptions or
Slide 3: Q4 investor webinar agenda
Q4 investor webinar agenda For personal use only • Address the recent changes to the Board and management of PYC • Provide an update on PYC’s drug development pipeline by asset • Phelan McDermid Syndrome (PYC-002) • Polycystic Kidney Disease (PYC-003) • Retinitis Pigmentosa type 11 (VP-001) • Autoso
Slide 4: PYC has built a pipeline of drug candidates with the potential to become the standard of care
PYC has built a pipeline of drug candidates with the potential to become the standard of care in areas of major unmet need Historical progress Progress expected in 20251 For personal use only Program Pre-clinical Clinical Prevalence2 PYC-003 Polycystic Kidney Disease 1 in 1,000 PYC-002 Phelan-McDerm
Slide 5: PYC's objectives over the coming months
PYC’s objectives over the coming 24 months Program 2026/2027 objectives1 For personal use only Polycystic Kidney Disease • Establish single dose human safety in healthy volunteers and PKD patients • Establish multiple dose human safety in PKD patients • Generate clinical proof-of-concept data (12-mo
Slide 6: Q&A
For personal use only Life-changing science Q&A
PYC Therapeutics — Investor Presentation (October 2025) on 6ix